Hum Gene Ther. 2016 Jul 15. [Epub ahead of print]

Stem cell therapy for the central nervous system in lysosomal storage diseases.

Siddiqi F¹, Wolfe JH^2,3.

Abstract

Neurological diseases with genetic etiologies result in the loss or dysfunction of neural cells throughout the central nervous system (CNS). Currently, few treatment options exist for the majority of neurogenetic diseases. Stem cell transplantation (SCT) into the CNS has the potential to be an effective treatment modality because progenitor cells may replace lost cells in the diseased brain, provide multiple trophic factors, or deliver missing proteins. This review focuses on the use of SCT in lysosomal storage diseases (LSDs), a large group of monogenic disorders with prominent CNS disease. In most patients the CNS disease results in intellectual disability that is refractory to current standard-of-care treatment. A large amount of preclinical work on brain-directed SCT has been has been performed in rodent LSD models. Cell types that have been used for direct delivery into the CNS include neural stem cells (NSCs), embryonic and induced pluripotent stem cells (ESCs and iPSCs), and mesenchymal stem cells (MSCs). Hematopoietic stem cells (HSCs) have been an effective therapy for the CNS in a few LSDs and may be augmented by overexpression of the missing gene. Current barriers and potential strategies to improve SCT for translation into effective patient therapies are discussed.